Company / Gross Profit
Vivos Therapeutics, Inc. Gross Profit History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$9.0M
FY2025
5-year range
$8.3M / $12.6M
FY2021-FY2025
Trend
+9.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit returned to growth in FY2025 after 2 years of decline, reaching $9M.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +0.8%.
Declined from $10M to $9M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- -10.6%
- 5-Year CAGR
- +0.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.8%, indicating consistent growth.
- In FY2025, gross profit increased 9.0% year-over-year.
- Peak gross profit was recorded in FY2022.
- Lowest gross profit in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.0M | +9.0% |
| FY2024 | $8.3M | -17.4% |
| FY2023 | $10.0M | -20.5% |
| FY2022 | $12.6M | +21.0% |
| FY2021 | $10.4M | +20.3% |
| FY2020 | $8.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026